Premium
Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis
Author(s) -
CastañoAmores Celia,
NietoGómez Pelayo
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14445
Subject(s) - medicine , azathioprine , sulfadiazine , toxoplasmosis , prednisone , dermatomyositis , pyrimethamine , rituximab , acute kidney injury , dermatology , surgery , immunology , antibiotics , chloroquine , disease , malaria , lymphoma , microbiology and biotechnology , biology
We observed a severe case of cerebral toxoplasmosis in a 22‐year‐old woman diagnosed with dermatomyositis in 2016 in Venezuela, and treated with rituximab and azathioprine. The patient met clinical and microbiological criteria. Treatment with pyrimethamine and sulfadiazine was initiated, and the patient was discharged. She was rehospitalized with signs and symptoms of a manic episode. During hospitalization, the patient developed acute kidney injury related to sulfadiazine crystalluria. Finally, acute kidney injury was resolved and the patient was successfully discharged.